مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

317
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

197
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

CYCLIC PAMIDRONATE THERAPY IN CHILDREN WITH OSTEOGENESIS IMPERFECTA

Pages

  6-12

Abstract

 The main objective of this study was to determine the efficacy and safety of PAMIDRONATE in improving bone mineralization and reducing fracture incidence in OSTEOGENESIS IMPERFECTA (OI).Materials and Methods: Intravenous PAMIDRONATE was administered to 64 children, aged 18 months to 10 years old, with severe OI, in a 1 Mg/kg single daily dose for 3 sequentional days at 4 month intervals, for over a period of 24-48 months. Clinical status, biochemical characteristics including bone turnover markers, the bone mineral density of the lumbar spine and femoral neck, and radiologic changes were assessed regularly during treatment.Results: The number of fractures decreased from median of 8 (range 4-11) to 0 fractures/year (range 0-4) (P<0.05). After 16 months of treatment, there was significant improvement in bone mineral density (BMD-DEXA) z-scores of the lumbar spine from median of -5.90 (range - 7.01 to -4.76) to -2.70 (range -4.46 to -1.98) (P<0.0001).Serum alkaline phosphatase (ALP) (bone formation marker) decreased from a median of 731.0 U/L (range 438-998 U/L) to 183 U/L (range 95-286 U/L) (P<0.001), implying a significant reduction in bone turnover and its resorption and increase in bone mineralization. There was no improvement either in their height growth velocities or in their standard deviation scores. Mobility and ambulation improved in all but 5 children, (all five took the drug for less than 2.5 years).There was a significant relief in chronic pain and fatigue but no adverse effects in any of the children using the drug.Conclusion: Cyclic PAMIDRONATE administration is effective in improving bone mineralization and reducing fracture incidence in childhood OSTEOGENESIS IMPERFECTA.

Multimedia

  • No record.

    • Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    SALEHPOUR, SH., & TAVAKOLI, S.. (2008). CYCLIC PAMIDRONATE THERAPY IN CHILDREN WITH OSTEOGENESIS IMPERFECTA. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM), 6(1), 6-12. SID. https://sid.ir/paper/297371/en

    Vancouver: Copy

    SALEHPOUR SH., TAVAKOLI S.. CYCLIC PAMIDRONATE THERAPY IN CHILDREN WITH OSTEOGENESIS IMPERFECTA. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM)[Internet]. 2008;6(1):6-12. Available from: https://sid.ir/paper/297371/en

    IEEE: Copy

    SH. SALEHPOUR, and S. TAVAKOLI, “CYCLIC PAMIDRONATE THERAPY IN CHILDREN WITH OSTEOGENESIS IMPERFECTA,” INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (IJEM), vol. 6, no. 1, pp. 6–12, 2008, [Online]. Available: https://sid.ir/paper/297371/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button